By now, investors clearly doubt that Tenet ( THC) can cure itself as planned.Last week, for the first time in nearly two years, investors finally got invited to Tenet headquarters to hear a detailed recovery plan in person. They responded by pushing the stock to its lowest price in more than a decade. Quite simply, Tenet failed to show skeptics how it will boost patient admissions in a tough industry environment. To hit its aggressive targets, Tenet must reverse a long trend of volume declines and start posting industry-leading admission growth instead. The company hopes to see patient admissions swing to a 1.5% rise in 2007 from an expected 2% drop this year. But investors are demanding more than promises. "The company didn't build the bridge from today to tomorrow and explain how they are going to get there," says Sheryl Skolnick, senior vice president of CRT Capital Group. "So the frustration level was quite high. ... I didn't get a sense of outright pessimism, like I have in the past, but there was still a sense of disbelief -- call it skepticism -- that was very strong." Tenet's full-day presentation sparked only one upgrade on Wall Street. Meanwhile, some analysts followed up by reiterating their underperform ratings on the stock even as it fell through their price targets. The stock slid another 17 cents to $6.23 on Friday. The shares now must more than double to hit the highest target on Wall Street. In the meantime, they continue to hover below the average Wall Street target of $7.